Plant-based production of recombinant Plasmodium surface protein pf38 and evaluation of its potential as a vaccine candidate

PLoS One. 2013 Nov 21;8(11):e79920. doi: 10.1371/journal.pone.0079920. eCollection 2013.

Abstract

Pf38 is a surface protein of the malarial parasite Plasmodium falciparum. In this study, we produced and purified recombinant Pf38 and a fusion protein composed of red fluorescent protein and Pf38 (RFP-Pf38) using a transient expression system in the plant Nicotiana benthamiana. To our knowledge, this is the first description of the production of recombinant Pf38. To verify the quality of the recombinant Pf38, plasma from semi-immune African donors was used to confirm specific binding to Pf38. ELISA measurements revealed that immune responses to Pf38 in this African subset were comparable to reactivities to AMA-1 and MSP119. Pf38 and RFP-Pf38 were successfully used to immunise mice, although titres from these mice were low (on average 1∶11.000 and 1∶39.000, respectively). In immune fluorescence assays, the purified IgG fraction from the sera of immunised mice recognised Pf38 on the surface of schizonts, gametocytes, macrogametes and zygotes, but not sporozoites. Growth inhibition assays using αPf38 antibodies demonstrated strong inhibition (≥60%) of the growth of blood-stage P. falciparum. The development of zygotes was also effectively inhibited by αPf38 antibodies, as determined by the zygote development assay. Collectively, these results suggest that Pf38 is an interesting candidate for the development of a malaria vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Protozoan / genetics*
  • Antigens, Protozoan / immunology
  • Enzyme-Linked Immunosorbent Assay
  • Fluorescent Antibody Technique
  • Malaria Vaccines / immunology*
  • Nicotiana / genetics*
  • Plantibodies / genetics*
  • Plantibodies / immunology
  • Plasmodium falciparum / growth & development
  • Plasmodium falciparum / immunology*
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / genetics
  • Recombinant Proteins / immunology

Substances

  • Antigens, Protozoan
  • Malaria Vaccines
  • Pf38 antigen, Plasmodium falciparum
  • Plantibodies
  • Recombinant Proteins

Grants and funding

This study was supported by the Fraunhofer Future Foundation (“Innovative technologies to manufacture ground-breaking biopharmaceutical products in microbes and plants”). Part of the study was funded by a grant of the Emmy Noether programme of the Deutsche Forschungsgemeinschaft and by the MALSIG consortium of the EU 7th framework programme (to GP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.